Musculoskeletal complication in kaposiform hemangioendothelioma without Kasabach–Merritt phenomenon: clinical characteristics and management

References

• CroteauSELiangMGKozakewichHPKaposiform heman-gioendothelioma: atypical features and risks of Kasabach–Merritt phenomenon in 107 referralsJ Pediatr2013162114214722871490
   PubMed Web of Science ®Google Scholar
• EnjolrasOWassefMMazoyerEInfants with Kasabach–Merritt syndrome do not have “true” hemangiomasJ Pediatr199713046316409108863
   PubMed Web of Science ®Google Scholar
• SarkarMMullikenJBKozakewichHPRobertsonRLBurrowsPEThrombocytopenic coagulopathy (Kasabach–Merritt phenomenon) is associated with kaposiform hemangioendothelioma and not with common infantile hemangiomaPlast Reconstr Surg19971006137713869385948
   PubMed Web of Science ®Google Scholar
• O’RaffertyCO’ReganGMIrvineADSmithOPRecent advances in the pathobiology and management of Kasabach–Merritt phenomenonBr J Haematol20151711385126123689
   PubMed Web of Science ®Google Scholar
• Fernandez-PinedaILopez-GutierrezJCChocarroGBernabeu-WittelJRamirez-VillarGLLong-term outcome of vincristine-aspirin-ticlopidine (VAT) therapy for vascular tumors associated with Kasabach–Merritt phenomenonPediatr Blood Cancer20136091478148123609996
   PubMed Web of Science ®Google Scholar
• EnjolrasOMullikenJBWassefMResidual lesions after Kasabach–Merritt phenomenon in 41 patientsJ Am Acad Dermatol2000422 Pt 122523510642677
   PubMed Web of Science ®Google Scholar
• BlattJStavasJMoats-StaatsBWoosleyJMorrellDSTreatment of childhood kaposiform hemangioendothelioma with sirolimusPediatr Blood Cancer20105571396139820730884
   PubMed Web of Science ®Google Scholar
• LiuXHLiJYQuXHTreatment of kaposiform hemangioendothelioma and tufted angiomaInt J Cancer201613971658166627252149
   PubMed Web of Science ®Google Scholar
• MaJShiQLJiangSJZhouHBZhouXJPrimary kaposiform hemangioendothelioma of a long bone: two cases in unusual locations with long-term follow upPathol Int201161638238621615616
   PubMed Web of Science ®Google Scholar
• JiYChenSXiangBSirolimus for the treatment of progressive kaposiform hemangioendothelioma: a multicenter retrospective studyInt J Cancer2017141484885528486787
   PubMed Web of Science ®Google Scholar
• JiYYangKPengSKaposiform haemangioendothelioma: clinical features, complications and risk factors for Kasabach–Merritt phenomenonBr J Dermatol Epub2018 330
   Web of Science ®Google Scholar
• FahrtashFMcCahonEArbuckleSSuccessful treatment of kaposiform hemangioendothelioma and tufted angioma with vincristineJ Pediatr Hematol Oncol201032650651020523249
   PubMed Web of Science ®Google Scholar
• UnoTItoSNakazawaAMiyazakiOMoriTTerashimaKSuccessful treatment of kaposiform hemangioendothelioma with everolimusPediatr Blood Cancer201562353653825306933
   PubMed Web of Science ®Google Scholar
• SchaeferBAWangDMerrowACDickieBHAdamsDMLong-term outcome for kaposiform hemangioendothelioma: a report of two casesPediatr Blood Cancer201764228428627701822
   PubMed Web of Science ®Google Scholar
• GrumanALiangMGMullikenJBKaposiform hemangioendothelioma without Kasabach–Merritt phenomenonJ Am Acad Dermatol200552461662215793511
   PubMed Web of Science ®Google Scholar
• OzaVSMamloukMDHessCPMathesEFFriedenIJRole of sirolimus in advanced kaposiform hemangioendotheliomaPediatr Dermatol2016332e88e9226864138
   PubMed Web of Science ®Google Scholar
• LyonsLLNorthPEMac-Moune LaiFStolerMHFolpeALWeissSWKaposiform hemangioendothelioma: a study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangiomaAm J Surg Pathol200428555956815105642
   PubMed Web of Science ®Google Scholar
• FujitaMMasonRJCoolCShannonJMHaraNFaganKAPulmonary hypertension in TNF-α-overexpressing mice is associated with decreased VEGF gene expressionJ Appl Physiol20029362162217012391106
   PubMed Web of Science ®Google Scholar
• O’SullivanBPLindenMDFrelingerALPlatelet activation in cystic fibrosisBlood2005105124635464115705796
   PubMed Web of Science ®Google Scholar
• DroletBATrenorCCBrandãoLRConsensus-derived practice standards plan for complicated kaposiform hemangioendotheliomaJ Pediatr2013163128529123796341
   PubMed Web of Science ®Google Scholar
• AdamsDMTrenorCCHammillAMEfficacy and safety of sirolimus in the treatment of complicated vascular anomaliesPediatrics20161372e2015325726783326
   PubMed Web of Science ®Google Scholar
• HammillAMWentzelMGuptaASirolimus for the treatment of complicated vascular anomalies in childrenPediatr Blood Cancer20115761018102421445948
   PubMed Web of Science ®Google Scholar
• ZhangGChenHGaoYLiuYWangJLiuXYSirolimus for treatment of kaposiform haemangioendothelioma with Kasabach–Merritt phenomenon: a retrospective cohort studyBr J Dermatol201817851213121429388191
   PubMed Web of Science ®Google Scholar
• WangCLiYXiangBSuccessful management of pancreatic kaposiform hemangioendothelioma with sirolimus: case report and literature reviewPancreas2017465e39e4128426496
   PubMed Web of Science ®Google Scholar
• OliveiraJGXavierPSampaioSMCompared to mycophenolate mofetil, rapamycin induces significant changes on growth factors and growth factor receptors in the early days post-kidney transplantationTransplantation200273691592011923692
   PubMed Web of Science ®Google Scholar
• BonegioRGFuhroRWangZRapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathyJ Am Soc Nephrol20051672063207215917339
   PubMed Web of Science ®Google Scholar
• WuMJWenMCChiuYTChiouYYShuKHTangMJRapamycin attenuates unilateral ureteral obstruction-induced renal fibrosisKidney Int200669112029203616732193
   PubMed Web of Science ®Google Scholar
• KorfhagenTRLe CrasTDDavidsonCRRapamycin prevents transforming growth factor-alpha-induced pulmonary fibrosisAm J Respir Cell Mol Biol200941556257219244201
   PubMed Web of Science ®Google Scholar
• ZhuJWuJFrizellERapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosisGastroenterology199911751198120410535884
   PubMed Web of Science ®Google Scholar
• NeefMLedermannMSaegesserHSchneiderVReichenJLow-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosisJ Hepatol200645678679617050028
   PubMed Web of Science ®Google Scholar
• CruzadoJMPovedaRIbernónMLow-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathyNephrol Dial Transplant201126113596360221393611
   PubMed Web of Science ®Google Scholar